Opinion|Videos|July 9, 2024
Unmet Needs in the Management of cGVHD
Hannah Choe, MD, provides insights on potential areas for improvement in developing more targeted and effective treatments for chronic GVHD.
Advertisement
Episodes in this series
Video content above is prompted by the following questions:
- How does the multisystemic nature of chronic GVHD (cGVHD), affecting skin, mucosa, and potentially other organs, complicate the management and treatment approach?
- What are the unmet needs and potential areas for improvement in terms of developing more targeted and effective treatments for cGVHD?
- What are the unmet needs and potential areas for improvement in terms of developing more targeted and effective treatments for cGVHD?
Advertisement
Related to this article
The phase 3 VERIFY trial found that rusfertide improved clinical response, reduced phlebotomy requirements, and eased symptom burden in patients with polycythemia vera receiving standard-of-care therapy.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Personalized mRNA Vaccine Intismeran Plus Pembro Cuts Melanoma Recurrence
2
Vopimetostat Plus Daraxonrasib Yields 82% ORR in MTAP-Deleted PDAC
3
Sunvozertinib Now Available in US for EGFR Exon 20 Insertion NSCLC
4
Rilvegostomig Combo Helped Some Patients Avoid Chemotherapy in Early Breast Cancer
5